Table 1.
Key Patient Characteristics
| Characteristic | L Arm (n = 45) |
LR Arm (n = 46) |
||
|---|---|---|---|---|
| No. of Patients | % | No. of Patients | % | |
| Age, years | ||||
| Median | 63 | 64 | ||
| Range | 34-85 | 36-89 | ||
| FLIPI | 36 | 35 | ||
| Low | 33.3 | 51.4 | ||
| Intermediate | 41.7 | 28.6 | ||
| High | 25.0 | 20.0 | ||
| TTP since last R dose, years | 1.6 | 1.4 | ||
| Stage | 45 | 45 | ||
| I/II | 22.3 | 33.4 | ||
| III/IV | 77.8 | 66.7 | ||
| LDH | 44 | 44 | ||
| > NL | 15.9 | 2.3 | ||
Abbreviations: FLIPI, Follicular Lymphoma International Prognostic Index; L, lenalidomide; LDH, lactate dehydrogenase; LR, lenalidomide plus rituximab; NL, normal limit; R, rituximab; TTP, time to progression.